Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ADAP - Adaptimmune Therapeutics Plc - ADR


IEX Last Trade
1.265
-0.005   -0.395%

Share volume: 984,730
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.27
-0.01
-0.39%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
10%
Profitability 0%
Dept financing 7%
Liquidity 50%
Performance 10%
Company vs Stock growth
vs
Performance
5 Days
4.96%
1 Month
-2.31%
3 Months
25.74%
6 Months
-21.12%
1 Year
54.88%
2 Year
-34.54%
Key data
Stock price
$1.26
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.42 - $2.05
52 WEEK CHANGE
$0.61
MARKET CAP 
324.797 M
YIELD 
N/A
SHARES OUTSTANDING 
255.745 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
BETA 
1.44
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,241,263
AVERAGE 30 VOLUME 
$2,344,522
Company detail
CEO:
Region: US
Website: https://www.adaptimmune.com/
Employees: 477
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.

Recent news